Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Cerebral Vasospasm

In brief

The purpose of this study is to evaluate the usefulness of adding Milrinone to the current standard treatment for cerebral vasospasm.

Key facts

Study ID

NCT02712788

Run by

Indiana University

People needed

4

Starts

2016-04-18

Expected to finish

2018-05-03

Last updated by the study team

2019-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects ≥ 18 years of age
• Aneurysmal subarachnoid hemorrhage, proven on CT angiogram or digital subtraction angiography
• Aneurysm treated, either by endovascular embolization or surgical clip ligation
• Evidence of increased velocities on transcranial dopplers (TCDs) and/or radiographic evidence of vasospasm as seen on angiogram
• Cerebral vasospasm as demonstrated by patient's clinical exam (new focal deficit or change in mental status not attributable to any other cause)

You may not qualify if…

• Recurrent subarachnoid hemorrhage
• Untreated ruptured aneurysm, for any reason
• Patients who die prior to treatment for aneurysm
• Patients who are not able to complete at least 6 months of follow-up
• Patients who are admitted already in vasospasm (i.e. a delayed admission)
• Creatinine clearance less than 20 ml/min
• Women with a positive pregnancy test or who are lactating
• Other comorbidity which may adversely affect patient outcome, at the discretion of the principal investigator

Where it is running

• Indiana University Heath Methodist Hospital — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.